Screener
Ionis Pharmaceuticals IONS Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Number of Investments | Less than 12 Months of Temporary Impairment / Estimated Fair Value | Less than 12 Months of Temporary Impairment / Unrealized Losses | More than 12 Months of Temporary Impairment / Estimated Fair Value | More than 12 Months of Temporary Impairment / Unrealized Losses | Total Temporary Impairment / Estimated Fair Value | Total Temporary Impairment / Unrealized Losses |
|---|---|---|---|---|---|---|---|
| Corporate debt securities | $303 | $659,038 | $(2,154) | $3,984 | $(12) | $663,022 | (2,166) |
| Debt securities issued by U.S. government agencies | 62 | 125,253 | (885) | 2,866 | (13) | 128,119 | (898) |
| Debt securities issued by the U.S. Treasury | 75 | 510,400 | (1,944) | - | - | 510,400 | (1,944) |
| Debt securities issued by states of the U.S. and political subdivisions of the states | 8 | 5,002 | (4) | - | - | 5,002 | (4) |
| Total temporarily impaired debt securities | $448 | $1,299,693 | $(4,987) | $6,850 | $(25) | $1,306,543 | (5,012) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Ionis Pharmaceuticals (IONS) reported cash, cash equivalents, and marketable securities of $1.31B in Q2 2026.
- How has Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities increased by 14.6% year-over-year, from $1.14B to $1.31B.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Ionis Pharmaceuticals's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude